Connect Biopharma Holdings Ltd. is a biopharmaceutical company focused on developing innovative therapies for the treatment of inflammatory diseases. As a leader in the life sciences sector, it leverages its proprietary T cell modulation technology to design and produce a pipeline of clinical-stage treatments. Connect Biopharma's strategic emphasis on targeting T cell-driven inflammatory pathways underscores its commitment to addressing unmet medical needs in conditions such as asthma, psoriasis, and inflammatory bowel disease.

The company's robust research and development efforts aim to provide improved therapeutic options through both monotherapies and combination therapies. Located in China, Connect Biopharma operates in the expansive global pharmaceutical market, accentuating its significance in introducing novel biologic treatments. Connect Biopharma's collaborations with research institutions and other biotech enterprises enhance its capacity to bring cutting-edge immunology solutions to healthcare providers and patients. With advancements in biotechnology continuously shaping the landscape of medical treatments, Connect Biopharma stands out as a pivotal player dedicated to adapting these innovations for critical health challenges.